{"title":"更正 \"阴离子肺表面活性物质磷脂的抗炎和抗病毒特性\"。","authors":"","doi":"10.1111/imr.13320","DOIUrl":null,"url":null,"abstract":"<p>Numata M, Kandasamy P, Voelker DR. The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids. <i>Immunol Rev</i>. 2023; 317: 166–186. doi:10.1111/imr.13207</p><p>In the article, the second paragraph was inadvertently added to Summary section and should have been removed.</p><p>The Summary reads:</p><p>The minor anionic pulmonary surfactant phospholipids, POPG and PI, exhibit anti-inflammatory effects as antagonists for multiple TLRs. These lipids also have strong efficacies as antivirals against multiple respiratory RNA-enveloped viruses such as RSV, IAVs, and SARS-CoV-2. PI also has a potent effect against non-enveloped virus (human rhinovirus A). These lipids also have very strong potential to be applied as anti-inflammatory compounds for acute lung injury, induced by cytokine storms, including severe COVID-19.</p><p>We determined the antiviral efficacy of POPG against five clinical isolates of RSV (designated by GenBank accession numbers) and recombinant strains of RSV (rA2-A2F, rA2-19F, and rA2 Long F) in comparison with RSV-A2.<sup>12</sup> The titer of each strain is shown as PFU/mL, and the efficacies of POPG and POPC (200 μg/mL) on each strain are stated as the viral titers by plaque assays. Data are shown as means ± SD from two independent experiments.</p><p>The Summary should read:</p><p>The minor anionic pulmonary surfactant phospholipids, POPG and PI, exhibit anti-inflammatory effects as antagonists for multiple TLRs. These lipids also have strong efficacies as antivirals against multiple respiratory RNA-enveloped viruses such as RSV, IAVs, and SARS-CoV-2. PI also has a potent effect against non-enveloped virus (human rhinovirus A). These lipids also have very strong potential to be applied as anti-inflammatory compounds for acute lung injury, induced by cytokine storms, including severe COVID-19.</p><p>We apologize for this error.</p>","PeriodicalId":178,"journal":{"name":"Immunological Reviews","volume":null,"pages":null},"PeriodicalIF":7.5000,"publicationDate":"2024-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imr.13320","citationCount":"0","resultStr":"{\"title\":\"Correction to “The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids”\",\"authors\":\"\",\"doi\":\"10.1111/imr.13320\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Numata M, Kandasamy P, Voelker DR. The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids. <i>Immunol Rev</i>. 2023; 317: 166–186. doi:10.1111/imr.13207</p><p>In the article, the second paragraph was inadvertently added to Summary section and should have been removed.</p><p>The Summary reads:</p><p>The minor anionic pulmonary surfactant phospholipids, POPG and PI, exhibit anti-inflammatory effects as antagonists for multiple TLRs. These lipids also have strong efficacies as antivirals against multiple respiratory RNA-enveloped viruses such as RSV, IAVs, and SARS-CoV-2. PI also has a potent effect against non-enveloped virus (human rhinovirus A). These lipids also have very strong potential to be applied as anti-inflammatory compounds for acute lung injury, induced by cytokine storms, including severe COVID-19.</p><p>We determined the antiviral efficacy of POPG against five clinical isolates of RSV (designated by GenBank accession numbers) and recombinant strains of RSV (rA2-A2F, rA2-19F, and rA2 Long F) in comparison with RSV-A2.<sup>12</sup> The titer of each strain is shown as PFU/mL, and the efficacies of POPG and POPC (200 μg/mL) on each strain are stated as the viral titers by plaque assays. Data are shown as means ± SD from two independent experiments.</p><p>The Summary should read:</p><p>The minor anionic pulmonary surfactant phospholipids, POPG and PI, exhibit anti-inflammatory effects as antagonists for multiple TLRs. These lipids also have strong efficacies as antivirals against multiple respiratory RNA-enveloped viruses such as RSV, IAVs, and SARS-CoV-2. PI also has a potent effect against non-enveloped virus (human rhinovirus A). These lipids also have very strong potential to be applied as anti-inflammatory compounds for acute lung injury, induced by cytokine storms, including severe COVID-19.</p><p>We apologize for this error.</p>\",\"PeriodicalId\":178,\"journal\":{\"name\":\"Immunological Reviews\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.5000,\"publicationDate\":\"2024-03-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imr.13320\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunological Reviews\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/imr.13320\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunological Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/imr.13320","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Correction to “The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids”
Numata M, Kandasamy P, Voelker DR. The anti-inflammatory and antiviral properties of anionic pulmonary surfactant phospholipids. Immunol Rev. 2023; 317: 166–186. doi:10.1111/imr.13207
In the article, the second paragraph was inadvertently added to Summary section and should have been removed.
The Summary reads:
The minor anionic pulmonary surfactant phospholipids, POPG and PI, exhibit anti-inflammatory effects as antagonists for multiple TLRs. These lipids also have strong efficacies as antivirals against multiple respiratory RNA-enveloped viruses such as RSV, IAVs, and SARS-CoV-2. PI also has a potent effect against non-enveloped virus (human rhinovirus A). These lipids also have very strong potential to be applied as anti-inflammatory compounds for acute lung injury, induced by cytokine storms, including severe COVID-19.
We determined the antiviral efficacy of POPG against five clinical isolates of RSV (designated by GenBank accession numbers) and recombinant strains of RSV (rA2-A2F, rA2-19F, and rA2 Long F) in comparison with RSV-A2.12 The titer of each strain is shown as PFU/mL, and the efficacies of POPG and POPC (200 μg/mL) on each strain are stated as the viral titers by plaque assays. Data are shown as means ± SD from two independent experiments.
The Summary should read:
The minor anionic pulmonary surfactant phospholipids, POPG and PI, exhibit anti-inflammatory effects as antagonists for multiple TLRs. These lipids also have strong efficacies as antivirals against multiple respiratory RNA-enveloped viruses such as RSV, IAVs, and SARS-CoV-2. PI also has a potent effect against non-enveloped virus (human rhinovirus A). These lipids also have very strong potential to be applied as anti-inflammatory compounds for acute lung injury, induced by cytokine storms, including severe COVID-19.
期刊介绍：
Immunological Reviews is a specialized journal that focuses on various aspects of immunological research. It encompasses a wide range of topics, such as clinical immunology, experimental immunology, and investigations related to allergy and the immune system.
The journal follows a unique approach where each volume is dedicated solely to a specific area of immunological research. However, collectively, these volumes aim to offer an extensive and up-to-date overview of the latest advancements in basic immunology and their practical implications in clinical settings.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
